Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002952 · ClinicalTrials.gov registry record · Phase 1

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

A Phase 1 study of Melanoma (Skin), sponsored by University of Chicago.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT00002952: Completed Phase 1 study of Melanoma (Skin), sponsored by University of Chicago.

NCT00002952 is a Phase 1 study of Melanoma (Skin) that has completed, run by University of Chicago. The registered enrollment target is 20 participants, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002952, a Phase 1 study of Melanoma (Skin), has completed, sponsored by University of Chicago.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Vaccines made from a tumor antigen gene may make the body build an immune response to kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cell to kill melanoma cells. Combining vaccine therapy with interleukin-12 may kill more melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy plus interleukin-12 in treating patients who have metastatic melanoma.

Conditions Studied

Melanoma (Skin)

Interventions

  • BIOLOGICAL recombinant interleukin-12
  • BIOLOGICAL MART-1 antigen
  • BIOLOGICAL recombinant MAGE-3.1 antigen

Study Locations (1)

Illinois

  • University of Chicago Cancer Research Center - Chicago

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 1997-01
Est. Completion 2002-11
Phase Phase 1
University of Chicago

796 total trials

What the finished NCT00002952 record still lists

NCT00002952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 136-participant average among 30 other Melanoma (Skin) trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Melanoma (Skin) appearing as the primary indexed condition, and to 3 interventions - of which recombinant interleukin-12 is the first listed.

NCT00002952 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT00002952 about?

NCT00002952 is a clinical study titled "Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma". RATIONALE: Vaccines made from a tumor antigen gene may make the body build an immune response to kill tumor cells. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cell to kill melanoma cells. Combining vaccine therapy with interleukin...

What is the current status of trial NCT00002952?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 1997-01. Estimated completion is 2002-11.

What conditions does trial NCT00002952 study?

This clinical trial studies the following conditions: Melanoma (Skin).

What interventions are being tested in trial NCT00002952?

The interventions under investigation include: recombinant interleukin-12 (BIOLOGICAL), MART-1 antigen (BIOLOGICAL), recombinant MAGE-3.1 antigen (BIOLOGICAL).

Who is sponsoring clinical trial NCT00002952?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002952 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma (Skin)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00002952's enrollment target sits among peer trials

20 21st of 30 higher than 6 of 30 other Melanoma (Skin) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Melanoma (Skin) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00002952, the US trial registry maintained by the National Library of Medicine. NCT00002952 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.